By Josh White
Date: Monday 03 Sep 2018
LONDON (ShareCast) - (Sharecast News) - Life science company SkinBioTherapeutics updated the market on its stability testing on Monday, reporting that the stability criteria required for its human study had been met.
The AIM-traded firm said it now expected to begin the study in September, as planned.
"Demonstrating the extended stability of the cream formulation was a key step to commencing the human study," said chief executive officer Dr Cath O'Neill.
"This remains on track to start this month."
Email this article to a friend
or share it with one of these popular networks: